Skip to main content
PMC home page
Journal of Clinical Laboratory Analysis logoLink to Journal of Clinical Laboratory Analysis
. 2009 Jan 12;23(1):63–69. doi: 10.1002/jcla.20291

Cellular immune response profile in patients with American tegumentary leishmaniasis prior and post chemotherapy treatment

Luiza C Reis 1, Maria Edilenza F Brito 1, Marina A Souza 1, Angela CR Medeiros 2, Claudio J Silva 3, Carlos F Luna 1, Valéria RA Pereira 1,✉
PMCID: PMC6649044  PMID: 19140214

Abstract

In this study, we have the objective of evaluating the lymphoproliferative response and determining interferon (IFN)‐γ and interleukin (IL)‐10 cytokine production in the peripheral blood mononuclear cells (PBMC) of patients with American tegumentary leishmaniasis prior and post 12 months of chemotherapy treatment with meglumine antimoniate compared with the PBMC of noninfected donors. Lymphoproliferation, such as cytokine production, was evaluated through in vitro stimulus with the soluble antigenic fraction from Leishmania (Viannia) braziliensis promastigotes (1.25 µg/ml) and Concanavalin A (2.5 µg/ml). Patients showed a significant lymphoproliferative response prior and post treatment compared with the control group. Similar result, prior to chemotherapy treatment, was observed in IFN‐γ and IL‐10 production when patients were compared with the control group. After chemotherapy treatment, PBMC lymphoproliferative response of the patients revealed an increase, whereas patients have shown a decrease in IFN‐γ levels and an increase in IL‐10, although without statistical difference. These results may indicate that the patients produced a specific cellular response to the soluble antigenic fraction suggesting that besides Th1 and Th2 dichotomy, immunological regulation mechanisms with the participation of memory T cells and regulatory T cells could be present in the clinical evolution of these patients. This understanding will allow the study and identification of new L. (V.) braziliensis molecules potentially candidates to vaccines. J. Clin. Lab. Anal. 23:63–69, 2009. © 2009 Wiley‐Liss, Inc.

Keywords: American tegumentary leishmaniasis, Leishmania (Viannia) braziliensis, cytokines, chemotherapy treatment, T lymphocytes

REFERENCES

  • 1. Rogers KA, Dekrey GK, Mbow ML, Gillespie RD, Brodskyn CI, Titus RG. Type 1 and type 2 responses to Leishmania major . FEMS Microbiol Lett 2002;209:1–7. [DOI] [PubMed] [Google Scholar]
  • 2. Holzmuller P, Bras‐Gonçalves R, Lemesre JR. Phenotypical characteristics, biochemical pathways, molecular targets and putative role of nitric oxide‐mediated programmed cell death in Leishmania . Parasitology 2006;132:S19–S32. [DOI] [PubMed] [Google Scholar]
  • 3. Reis LC, Brito MEF, Souza MA, Pereira VRA. Immunological mechanisms in the cellular and humoral response in the American tegumentary leishmaniasis. Rev Patol Trop 2006;35:103–115. [Google Scholar]
  • 4. Bogdan C, Rollinghoff M. The immune response to Leishmania: Mechanisms of parasite control and evasion. Int J Parasitol 1998;28:121–134. [DOI] [PubMed] [Google Scholar]
  • 5. Gontijo B, Carvalho MLR. American cutaneous leishmaniasis. Rev Soc Bras Med Trop 2003;36:71–80. [DOI] [PubMed] [Google Scholar]
  • 6. Armijos RX, Weigel MM, Calvopina M, Mancheno M, Rodríguez R. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis. Acta Trop 2004;91:153–160. [DOI] [PubMed] [Google Scholar]
  • 7. Yardley V, Ortuno N, Llanos‐Cuentas A, et al. American tegumentary leishmaniasis: Is antimonial treatment outcome related to parasite drug susceptibility? J Infect Dis 2006;194:1168–1175. [DOI] [PubMed] [Google Scholar]
  • 8. Coler RN, Reed SG. Second‐generation vaccines against leishmaniasis. Trends Parasitol 2005;21:244–249. [DOI] [PubMed] [Google Scholar]
  • 9. Haberer JE, Da‐Cruz AM, Soong L, et al. Leishmania pifanoi amastigote antigen p‐4: Epitopes involved in t‐cell responsiveness in human cutaneous leishmaniasis. Infect Immun 1998;66:3100–3105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Da‐Cruz AM, Bittar R, Mattos M, et al. T‐cell mediated immune responses in patients with cutaneous or mucosal leishmaniasis: Long‐term evaluation after therapy. Clin Diagn Lab Immunol 2002;9:251–256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Telino E, De Luca PM, Matos DC, et al. In vitro responses of human peripheral blood mononuclear cells to whole‐cell, particulate and soluble extracts of Leishmania promastigotes. Clin Exp Immunol 2005;143:338–344. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Toledo VPCP, Mayrink W, Gollob KJ, et al. Immunochemotherapy in American cutaneous leishmaniasis: Immunological aspects before and after treatment. Mem Inst Oswaldo Cruz 2001;96:89–98. [DOI] [PubMed] [Google Scholar]
  • 13. Brito ME, Mendonça MG, Gomes YM, Jardim ML, Abath FG. Dynamics of the antibody response in patients with therapeutic or spontaneous cure of American cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 2001;95:203–206. [DOI] [PubMed] [Google Scholar]
  • 14. Passos VM, Fernandes O, Lacerda PA, et al. Leishmania (Viannia) braziliensis is the predominant species infecting patients with American cutaneous leishmaniasis in the tate of Minas Gerais, Southeast Brazil. Acta Trop 1999;72:251–258. [DOI] [PubMed] [Google Scholar]
  • 15. Coutinho SG, Pirmez C, Da‐Cruz AM. Parasitological and immunological follow‐up of American tegumentary leishmaniasis patients. Trans R Soc Trop Med Hyg 2002;96:S173–S178. [DOI] [PubMed] [Google Scholar]
  • 16. Passos VM, Barreto SM, Romanha AJ, et al. Cutaneous leishmaniasis in the Metropolitan Region of Belo Horizonte: Clinical, laboratorial, therapeutic and prognosis features (1989–1995). Rev Soc Bras Med Trop 2001;34:5–12. [DOI] [PubMed] [Google Scholar]
  • 17. Oliveira‐Neto MP, Schubach A, Mattos M, Gonçalves‐Costa SC, Pirmez C. A low‐dose antimony treatment in 159 patients with American cutaneous leishmaniasis: Extensive follow‐up studies (up to 10 years). Am J Trop Med Hyg 1997;57:651–655. [DOI] [PubMed] [Google Scholar]
  • 18. Fundação Nacional de Saúde . Guia de Vigilância Epidemiológica. Brasília: Ministério da Saúde; 2002. [Google Scholar]
  • 19. Mendonça MG, Brito MEF, Rodrigues EH, Bandeira V, Jardim ML, Abath FG. Persistence of Leishmania parasites in scars after clinical cure of American cutaneous leishmaniasis: Is there a sterile cure? J Infect Dis 2004;189:1018–1023. [DOI] [PubMed] [Google Scholar]
  • 20. Schubach A, Haddad F, Oliveira‐Neto MP, et al. Detection of Leishmania DNA by polymerase chain reaction in scars of treated human patients. J Infect Dis 1998;178:911–914. [DOI] [PubMed] [Google Scholar]
  • 21. Berger BJ, Fairlamb AH. Interactions between immunity and chemotherapy in the treatment of the trypanosomiases and leishmaniasis. Parasitology 1992;105:S71–S78. [DOI] [PubMed] [Google Scholar]
  • 22. Conceição‐Silva F, Dórea RC, Pirmez C, Schubach A, Coutinho SG. Quantitative study of Leishmania braziliensis braziliensis reactive T cells in peripheral blood and in the lesions of patients with American cutaneous leishmaniasis. Clin Exp Immunol 1990;79:221–226. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Coutinho SG, Oliveira MP, Da‐Cruz AM, et al. T‐cell responsiveness of American cutaneous leishmaniasis patients to purified Leishmania pifanoi amastigote antigens and Leishmania braziliensis promastigote antigens: Immunologic patterns associated with cure. Exp Parasitol 1996;84:144–155. [DOI] [PubMed] [Google Scholar]
  • 24. Carvalho EM, Johnson WD, Barreto E, et al. Cell mediated immunity in American cutaneous and mucosal leishmaniasis. J Immunol 1985;135:4144–4148. [PubMed] [Google Scholar]
  • 25. Mendonça SC, Coutinho SG, Amendoeira RR, Marzochi MC, Pirmez C. Human American cutaneous leishmaniasis (Leishmania b. braziliensis) in Brazil: Lymphoproliferative responses and influence of therapy. Clin Exp Immunol 1986;64:269–276. [PMC free article] [PubMed] [Google Scholar]
  • 26. Coutinho SG, Da‐Cruz AM, Bertho AL, Santiago MA, De‐Luca P. Immunologic patterns associated with cure in human American cutaneous leishmaniasis. Braz J Med Biol Res 1998;31:139–142. [DOI] [PubMed] [Google Scholar]
  • 27. Da‐Cruz AM, Conceicao‐Silva F, Bertho AL, Coutinho SG. Leishmania‐reactive CD4+ and CD8+ T cells associated with cure of human cutaneous leishmaniasis. Infect Immun 1994;62:2614–2618. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Scott P. Immunologic memory in cutaneous leishmaniasis. Cell Microbiol 2005;7:1707–1713. [DOI] [PubMed] [Google Scholar]
  • 29. Scott P, Artis D, Uzonna J, Zaph C. The development of effector and memory T cells in cutaneous leishmaniasis: The implications for vaccine development. Immunol Rev 2004;201:318–338. [DOI] [PubMed] [Google Scholar]
  • 30. Antonelli LR, Dutra OW, Almeida RP, Bacellar O, Gollob KJ. Antigen specific correlations of cellular immune responses in human leishmaniasis suggests mechanisms for immunoregulation. Clin Exp Immunol 2004;136:341–348. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Paul WE. T‐lymphocyte differentiation and biology In: Paul W, editor. Fundamental Immunology. Philadelphia, PA: Lippincott‐Raven; 1999. [Google Scholar]
  • 32. Ribeiro‐de‐Jesus A, Almeida RP, Lessa H, Bacellar O, Carvalho EM. Cytokine profile and pathology in human leishmaniasis. Braz J Med Biol Res 1998;31:143–148. [DOI] [PubMed] [Google Scholar]
  • 33. Pompeu MM, Brodskyn C, Teixeira MJ, et al. Differences in gamma interferon production in vitro predict the pace of the in vivo response to Leishmania amazonensis in healthy volunteers. Infect Immun 2001;69:7453–7460. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Belkaid Y, Piccirillo CA, Mendez S, Shevach E, Sacks DL. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 2002;420:502–507. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Laboratory Analysis are provided here courtesy of Wiley

RESOURCES